Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Caribou Biosciences Expands Clinical Development Of CB-010 With FDA Clearance Of IND In Lupus
Caribou Biosciences 扩大了 CB-010 的临床开发，美国食品药品管理局批准了狼疮 IND
-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 --
— FDA 已批准 Caribou 针对狼疮肾炎和肾外狼疮的 CB-010 的临床试验申请；GALLOP 1 期临床试验预计将于 2024 年启动 —
-- Driven by encouraging initial safety and efficacy in the ongoing ANTLER trial for r/r B-NHL, CB-010 clinical development has expanded to include autoimmune diseases --
— 在正在进行的 r/r B-NHL ANTLER 试验的初始安全性和有效性令人鼓舞的推动下，CB-010 的临床开发已扩展到包括自身免疫性疾病——
-- Advancing ANTLER Phase 1 trial for 2L LBCL; initial dose expansion data to be shared at a medical congress in Q2 2024 --
— 推进 2L LBCL 的 ANTLER 1 期试验；初始剂量扩展数据将在2024年第二季度的医学大会上共享 —
-- Conference call and webcast scheduled for today at 5:00 pm ET --
— 电话会议和网络直播定于今天美国东部时间下午 5:00 举行——
BERKELEY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
加利福尼亚州伯克利，2024年4月4日（GL...
登录免费看全文
登录/注册